Elsevier

Atherosclerosis

Volume 252, September 2016, Pages 106-115
Atherosclerosis

Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis

https://doi.org/10.1016/j.atherosclerosis.2016.06.039Get rights and content

Highlights

  • Bisphosphonates might reduce cardiovascular risk due to their ability to reduce calcification in arterial walls.

  • This meta-analysis of randomized controlled trials showed that bisphosphonates reduce arterial wall calcification.

  • Bisphosphonates have no effect on arterial stiffness or on cardiovascular events.

  • Bisphosphonates tend to reduce the risk of cardiovascular mortality and reduce all-cause mortality in various patient groups.

Abstract

Background and aims

Bisphosphonates might be effective in reducing cardiovascular events due to their ability to reduce calcification in arterial walls. We aimed to investigate the effects of treatment with bisphosphonates on the prevention of atherosclerotic processes and cardiovascular disease.

Methods

Pubmed, Embase and the Cochrane Library were systematically reviewed by two independent investigators for randomized controlled studies published up to January 2016, in which the effect of bisphosphonates on arterial wall disease, cardiovascular events, cardiovascular mortality or all-cause mortality were reported. There was no restriction for the type of population used in the trials. Random-effects models were used to calculate the pooled estimates.

Results

61 trials reporting the effects of bisphosphonates on the outcomes of interest were included. Bisphosphonates had beneficial effects on arterial wall disease regarding arterial calcification (pooled mean percentage difference of 2 trials −11.52 (95% CI -16.51 to −6.52, p < 0.01, I2 13%), but not on arterial stiffness (pooled mean percentage difference of 2 trials −2.82; 95% CI -10.71–5.07; p = 0.48, I2 59%). No effect of bisphosphonate treatment on cardiovascular events was found (pooled RR of 20 trials 1.03; 95% CI 0.91–1.17, I2 16%), while a lower risk for cardiovascular mortality was observed in patients treated with bisphosphonates (pooled RR of 10 trials 0.81; 95% CI 0.64–1.02; I2 0%) although not statistically significant. Patients treated with bisphosphonates had a reduced risk of all-cause mortality (pooled RR of 48 trials 0.90; 95% CI 0.84–0.98; I2 53%).

Conclusions

In this systematic review and meta-analysis it is shown that bisphosphonates reduce arterial wall calcification but have no effect on arterial stiffness or on cardiovascular events. Bisphosphonates tend to reduce the risk of cardiovascular mortality and reduce all-cause mortality in various patient groups, including osteoporosis and cancer patients.

Introduction

Despite improvements in treatment of cardiovascular risk factors cardiovascular disease still results in an immense disease burden [1]. New treatment targets could further reduce the risk for first and subsequent cardiovascular events. As vascular calcifications are related to an increased cardiovascular risk, preventing or reducing arterial calcification might be an important target for further cardiovascular risk reduction [2]. Arterial calcifications are observed in several common conditions such as diabetes mellitus, renal failure and aging, all conditions known to be related to a high cardiovascular risk [3].

Osteoporosis is related to a 2-fold increased risk of cardiovascular mortality, also known as the ‘bone-vascular axis’ [4], [5], [6], [7], [8]. The process of arterial calcification might play an important role in this relation [9]. Arterial calcification is regulated through a network of inhibitory (and promoting) pathways, such as vitamin K dependent pathways, the Klotho protein, Fetuin-A and pyrophosphate [10]. Pyrophosphate is a strong inhibitor of arterial calcification [11], [12] and bisphosphonates, well-established drugs for the treatment of bone diseases associated with excessive bone resorption including osteoporosis and bone metastasis, are pyrophosphate analogues and could thus stimulate the inhibitory effects of pyrophosphate on arterial calcification [13], [14]. In fact, bisphosphonates were first shown to reduce arterial calcification and soft tissues calcification in rats [15].

Therefore it is conceivable that bisphosphonates interfere in the arterial calcification process and might be able to reduce the risk of cardiovascular disease [16]. Support for this hypothesis is growing as cohort studies show that the use of bisphosphonates in patients with maximum adherence is associated with a 20% lower risk of acute myocardial infarction [17] and randomized controlled trials such as the Health Outcomes and Reduced Incidence with Zolendronic Acid Once Yearly (HORIZON) trial show an 11% reduction of risk of cardiovascular events and a 31% reduction of cardiovascular deaths was found after treatment with bisphosphonates compared to placebo [18].

To investigate the effects of treatment with bisphosphonates on arterial wall calcification and stiffness, cardiovascular events, cardiovascular mortality and all-cause mortality, we performed a systematic review of randomized controlled trials with no restrictions on populations and summarized the results in a meta-analysis.

Section snippets

Search strategy

A systematic literature search of Medline, Embase and the Cochrane Library was performed reviewing articles published up to January 2016. A search filter was designed using synonyms for the determinant (bisphosphonates) and outcome (surrogate markers of cardiovascular disease such as arterial stiffness and arterial calcification, cardiovascular events, cardiovascular mortality, survival and mortality) and using synonyms for determinant (bisphosphonates) and randomized controlled trials. A full

Results

The search strategy identified 6573 unique articles. Initial screening on title and abstract decreased this number to 353 potentially relevant studies. After evaluation of these articles in more detail using the full-text, 292 articles were excluded for reasons shown in Fig. 1. No additional articles were identified through manual reference check, resulting in a total number of 61 articles for meta-analysis [18], [19], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35]

Discussion

This systematic review and meta-analysis included 61 randomized controlled trials using various patient groups including osteoporosis patients and cancer patients. 45 studies were placebo-controlled, while the other 16 trials used standard of care without bisphosphonates as the control group. Two studies reported on surrogate markers of cardiovascular disease and showed that bisphosphonates reduce arterial wall calcification, but have no effect on arterial stiffness. Also, no effects of

Conflict of interest

The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

Acknowledgments

All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

References (98)

  • A.H.G. Paterson et al.

    Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

    Lancet Oncol.

    (2012)
  • H.J. Meulenbeld et al.

    Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate Cancer (CRPC), the Netherlands prostate study (NePro)

    Eur. J. Cancer

    (2012)
  • R. Coleman et al.

    Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

    Lancet Oncol.

    (2014)
  • M. Gnant et al.

    Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

    Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO

    (2015)
  • S. Adami et al.

    Efficacy and safety of ibandronate given by intravenous injection once every 3 months

    Bone

    (2004)
  • L.H. Klotz et al.

    A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study

    Eur. Urol.

    (2013)
  • R. Lahtinen et al.

    Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

    Lancet (London, England)

    (1992)
  • E.S. Orwoll et al.

    Efficacy and safety of monthly ibandronate in men with low bone density

    Bone

    (2010)
  • P. Ravn et al.

    The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

    Bone

    (1996)
  • R. Recker et al.

    Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

    Bone.

    (2004)
  • K.T. Smerud et al.

    A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation

    Am. J. Transplant.

    (2012)
  • D. Tripathy et al.

    Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial

    Ann. Oncol.

    (2004)
  • K.A. Lomashvili et al.

    Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure

    Kidney Int.

    (2009)
  • S. Gonnelli et al.

    Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women

    Bone

    (2014)
  • K. Okamoto et al.

    Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study

    Life Sci.

    (2010)
  • P.Y. Lu et al.

    Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate

    Clin. Ther.

    (2011)
  • D. Mozaffarian et al.

    Heart disease and stroke Statistics-2015 update: a report from the American heart association

    Circulation

    (2015)
  • R.J. Rennenberg et al.

    Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis

    Vasc. Health Risk Manag.

    (2009)
  • P. Lanzer et al.

    Medial vascular calcification revisited: review and perspectives

    Eur. Heart J.

    (2014)
  • L.B. Tanko et al.

    Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women

    Calcif. Tissue Int.

    (2003)
  • M.T. Vogt et al.

    Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures

    J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.

    (1997)
  • M. van der Klift et al.

    Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study

    Calcif. Tissue Int.

    (2002)
  • B. Thompson et al.

    Arterial calcification and bone physiology: role of the bone-vascular axis

    Nat. Rev. Endocrinol.

    (2012)
  • H. Fleisch et al.

    Inhibition of aortic calcification by means of pyrophosphate and polyphosphates

    Nature

    (1965)
  • M. Bevilacqua et al.

    Bisphosphonates and atherosclerosis: why?

    Lupus

    (2005)
  • R. Schenk et al.

    Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

    Calcif. Tissue Res.

    (1973)
  • L.L. Santos et al.

    Vascular effects of bisphosphonates-a systematic review

    Clin. Med. Insights: Endocrinol. Diabetes

    (2012)
  • P. Vestergaard

    Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?

    Calcif. Tissue Int.

    (2012)
  • K.W. Lyles et al.

    Zoledronic acid and clinical fractures and mortality after hip fracture

    N. Engl. J. Med.

    (2007)
  • D.M. Black et al.

    Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

    N. Engl. J. Med.

    (2007)
  • J.P.T. Higgins et al.

    The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

    (2011)
  • D. Moher et al.

    Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement

    Lancet

    (1896-1900)
  • A.R. Belch et al.

    Effect of daily etidronate on the osteolysis of multiple myeloma

    J. Clin. Oncol.

    (1991)
  • A.T. van Holten-Verzantvoort et al.

    Palliative pamidronate treatment in patients with bone metastases from breast cancer

    J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.

    (1993)
  • J.R. Berenson

    The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma

    Rev. Contemp. Pharmacother.

    (1998)
  • G.N. Hortobagyi et al.

    Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate

    J. Clin. Oncol.

    (1998)
  • R.L. Theriault et al.

    Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial

    J. Clin. Oncol.

    (1999)
  • B. Kristensen et al.

    Oral clodronate in breast cancer patients with bone metastases: a randomized study

    J. Intern. Med.

    (1999)
  • T. Saarto et al.

    Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial

    J. Clin. Oncol.

    (2001)
  • Cited by (100)

    • The forgotten link between atherosclerosis and bone disease

      2022, Archives of Cardiovascular Diseases
    • Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study

      2022, Bone
      Citation Excerpt :

      The literature also suggests that periodic inflammation stimulated by bisphosphonates may increase resistance to a subsequent inflammatory disease [43]. However, current reports provide no evidence of reduced cardiovascular events after the administration of bisphosphonates [44]. A previous study revealed that bisphosphonate treatment reduced mortality by 28% in patients after hip fracture, but only 8% of this reduction may be due to fracture prevention [18].

    • The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease

      2021, Journal of the Formosan Medical Association
      Citation Excerpt :

      Nonetheless, it appeared that the adverse association was evident compared with other classes of anti-osteoporotic agents. There is also evidence from trials that have suggested that BPs reduce the risk of cardiovascular disease,12,28–30 and some observational studies have supported the possibility of a reduced risk of AMI.11,13,31,32 Regarding the issue of hospitalization for AF, serious AF events were observed more commonly among patients who received zoledronic acid for more than 3 months in the HORIZON-PFT.14

    View all citing articles on Scopus
    View full text